Summary

Bevacizumab (BEV) is the first targeted agent that when added to standard chemotherapy improved overall survival (OS) in women with metastatic or relapsed cervical cancer. This finding from a randomized, open-label Phase 3 study represents the first instance in which a targeted therapy has significantly prolonged survival in this setting. This article discusses the The Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer study of the Gynecological Oncology Group [GOG 240; NCT00803062; Tewari KS et al. J Clin Oncol 2013 (suppl; abstr 3)].